Trial record 34 of 117 for: "Connective Tissue Disease" | "Methylprednisolone"
A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567.
|ClinicalTrials.gov Identifier: NCT02512575|
Recruitment Status : Completed
First Posted : July 31, 2015
Results First Posted : October 4, 2018
Last Update Posted : October 4, 2018
Information provided by (Responsible Party):
|Study Design||Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Single (Participant); Primary Purpose: Basic Science|
Drug: AZD9567 Monohydrat
Drug: Placebo oral suspension/ Placebo capsule
|Recruitment Details||Phase 1, single-center (Berlin), randomized, single-blind, placebo-controlled study carried on 72 healthy male participants (8 subjects per cohort). In Cohort 1-8, participants were randomized to AZD9567:placebo (6:2). In Cohort 9, participants were randomized to prednisolone:placebo (6:2). Participants received treatment in a fasted state|
|Pre-assignment Details||Screening period (Day -28 to Day -3). For Cohort 7, screening period was up to 21 days|